Abstract
Heterozygous SORL1 protein truncating variants (PTV) are a strong risk factor for early-onset Alzheimer's disease (EOAD). In case control studies performed at the genome-wide level, PTV definition is usually straightforward. Regarding splice site variants, only those affecting canonical sites are typically included. Some other variants, not annotated as PTV, could, however, affect splicing and hence result in a loss of SORL1 function. We took advantage of the whole exome sequencing data from the 9/484 patients with a previously reported SORL1 PTV in the French EOAD series and searched for a second variant which may affect splicing and eventually result in more than 50% loss of function overall. We found that one patient, known to carry a variant predicted to disrupt the canonical 5' splice site of exon 8, also carried a second novel intronic variant predicted to affect SORL1 splicing of exon 29. Segregation analysis showed that the second variant was located in trans from the known PTV. We performed ex vivo minigene splicing assays and showed that both variants led to the generation of transcripts containing a premature stop codon. This is therefore the first evidence of a human carrying biallelic SORL1 PTV. This patient had a ...Continue Reading
References
Sep 22, 2005·Proceedings of the National Academy of Sciences of the United States of America·Olav M AndersenThomas E Willnow
Jan 16, 2007·Nature Genetics·Ekaterina RogaevaPeter St George-Hyslop
Apr 26, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Guy M McKhannCreighton H Phelps
Apr 5, 2012·Molecular Psychiatry·C PottierUNKNOWN PHRC GMAJ Collaborators
Apr 6, 2012·Journal of Alzheimer's Disease : JAD·David WallonUNKNOWN collaborators of GMAJ project
Nov 16, 2012·The New England Journal of Medicine·Thorlakur JonssonKari Stefansson
Nov 16, 2012·The New England Journal of Medicine·Rita GuerreiroUNKNOWN Alzheimer Genetic Analysis Group
Feb 6, 2013·Journal of Alzheimer's Disease : JAD·Cyril PottierDidier Hannequin
Feb 14, 2014·Science Translational Medicine·Safak CaglayanThomas E Willnow
Jul 6, 2014·Clinical Genetics·B A ThompsonA B Spurdle
Nov 11, 2014·Annals of Neurology·Badri N VardarajanRichard Mayeux
Mar 26, 2015·Nature Genetics·Stacy SteinbergKari Stefansson
Jun 4, 2015·BMC Biotechnology·Ken Motohashi
Jul 5, 2015·Lancet Neurology·Elise CuyversKristel Sleegers
Aug 26, 2015·Molecular Psychiatry·G NicolasUNKNOWN CNR-MAJ collaborators
Jan 14, 2016·PLoS Genetics·Omar SoukariehAlexandra Martins
Mar 31, 2016·Acta Neuropathologica·Jan VerheijenKristel Sleegers
Apr 3, 2016·Neurology·Kilan Le GuennecUNKNOWN CNR-MAJ collaborators
Aug 19, 2016·Nature·Monkol LekUNKNOWN Exome Aggregation Consortium
Nov 9, 2016·Neurology. Genetics·Michael L CuccaroMargaret A Pericak-Vance
Dec 14, 2016·Molecular Psychiatry·K Le GuennecA Rovelet-Lecrux
Dec 22, 2016·Human Heredity·Gaël NicolasDominique Campion
Mar 30, 2017·PLoS Medicine·Hélène-Marie LanoiseléeUNKNOWN collaborators of the CNR-MAJ project
May 26, 2017·European Journal of Human Genetics : EJHG·Henne HolstegePhilip Scheltens
Jun 10, 2017·Acta Neuropathologica Communications·Håkan ThonbergCaroline Graff
Aug 10, 2017·Neurobiology of Aging·Céline BellenguezUNKNOWN CNR MAJ collaborators
Citations
Mar 19, 2020·BMC Psychiatry·Xiao LiZhe Li
Jan 27, 2019·Scientific Reports·Peder MadsenMorten S Nielsen
Mar 27, 2019·Acta Neuropathologica·Dominique CampionGaël Nicolas
May 21, 2020·International Journal of Molecular Sciences·Eva BagyinszkySeongSoo A An
Oct 21, 2020·Molecular Brain·Karissa BarthelsonMichael Lardelli
Mar 6, 2021·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Julie HoogmartensChristine Van Broeckhoven